| Target Price | $54.06 |
| Price | $54.28 |
| Deviation |
0.41%
register free of charge
|
| Number of Estimates | 26 |
|
26 Analysts have issued a price target Bristol-Myers Squibb 2026 .
The average Bristol-Myers Squibb target price is $54.06.
This is
0.41%
register free of charge
$71.40
31.54%
register free of charge
$33.43
38.41%
register free of charge
|
|
| A rating was issued by 34 analysts: 11 Analysts recommend Bristol-Myers Squibb to buy, 21 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Bristol-Myers Squibb stock has an average upside potential 2026 of
0.41%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 48.30 | 48.41 |
| 7.32% | 0.23% | |
| EBITDA Margin | 42.27% | 36.04% |
| 4.43% | 14.74% | |
| Net Margin | -18.53% | 27.78% |
| 203.90% | 249.95% |
29 Analysts have issued a sales forecast Bristol-Myers Squibb 2025 . The average Bristol-Myers Squibb sales estimate is
This results in the following potential growth metrics:
16 Analysts have issued an Bristol-Myers Squibb EBITDA forecast 2025. The average Bristol-Myers Squibb EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
29 Bristol-Myers Squibb Analysts have issued a net profit forecast 2025. The average Bristol-Myers Squibb net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.41 | 6.61 |
| 214.25% | 249.89% | |
| P/E | 8.22 | |
| EV/Sales | 2.95 |
29 Analysts have issued a Bristol-Myers Squibb forecast for earnings per share. The average Bristol-Myers Squibb EPS is
This results in the following potential growth metrics and future valuations:
Bristol-Myers Squibb...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B of A Securities |
Locked
➜
Locked
|
Locked | Dec 15 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Dec 12 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Dec 12 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Dec 10 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Dec 04 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Dec 02 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B of A Securities:
Locked
➜
Locked
|
Dec 15 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Dec 12 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Dec 12 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Dec 10 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Dec 04 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Dec 02 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 17 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


